Ubrelvy is a prescription medication used for the acute treatment of migraine attacks in adults, with or without aura. It is not a daily preventive medication. You take it when a migraine starts, and it works by blocking a protein involved in migraine pain signaling.
How Ubrelvy Treats Migraines
During a migraine, the brain releases a protein called CGRP (calcitonin gene-related peptide) that triggers inflammation and pain in the nerves surrounding the brain. Ubrelvy is a CGRP receptor antagonist, meaning it blocks CGRP from attaching to its receptors. This interrupts the pain cascade that drives a migraine attack. Unlike older migraine medications called triptans, which work by narrowing blood vessels, Ubrelvy targets the pain pathway directly without affecting blood vessels, making it an option for people with cardiovascular concerns who can’t take triptans.
Ubrelvy belongs to a class of drugs called “gepants.” It was the first oral CGRP receptor antagonist approved by the FDA for acute migraine treatment. Lab studies show it has extremely high binding affinity and selectivity for the human CGRP receptor, meaning it locks onto that specific target without interfering much with related receptors in the body.
Acute Treatment, Not Prevention
An important distinction: Ubrelvy is specifically approved for treating migraine attacks that have already started. It is not indicated for preventing migraines from occurring. If you experience frequent migraines and need a preventive medication, that requires a different treatment. However, some people use Ubrelvy for acute relief alongside a separate preventive migraine medication. Research from the American Headache Society supports this combination approach as both safe and effective when the two treatments serve their distinct roles.
How Well It Works
Ubrelvy comes in two doses: 50 mg and 100 mg tablets. Both doses have been studied in large clinical trials. If the first dose doesn’t fully relieve your migraine, you can take a second dose at least two hours after the first. The maximum amount in a 24-hour period is 200 mg. Your doctor may start you at 50 mg and adjust based on how you respond.
Common Side Effects
Ubrelvy is generally well tolerated. In clinical trials involving nearly 1,500 patients across the two dose strengths, the most common side effects occurring more often than placebo were nausea and drowsiness. At the 100 mg dose, 4% of patients reported nausea (compared to 2% on placebo) and 3% reported drowsiness or fatigue (compared to 1% on placebo). Dry mouth occurred in about 2% of those taking the higher dose. At the 50 mg dose, side effects were milder and closer to placebo rates.
These numbers mean most people taking Ubrelvy don’t experience noticeable side effects. The drowsiness is worth noting if you plan to drive or work after taking it, particularly at the 100 mg dose.
Drug Interactions to Know About
Ubrelvy is broken down in the body by a liver enzyme called CYP3A4. Certain medications that strongly block this enzyme can cause Ubrelvy to build up to unsafe levels in your bloodstream. Taking Ubrelvy with these medications is contraindicated, meaning you should not combine them at all. The most common ones include:
- Ketoconazole, an antifungal medication
- Itraconazole, another antifungal
- Clarithromycin, an antibiotic
Other strong CYP3A4 inhibitors exist beyond this list. If you take any prescription medications regularly, your doctor or pharmacist can check whether they interact with Ubrelvy before you start using it. Medications that moderately affect this enzyme may require a dose adjustment rather than complete avoidance.
Who Can and Can’t Take Ubrelvy
Ubrelvy is approved for adults 18 and older. It has not been approved for use in children or adolescents. Because it doesn’t constrict blood vessels the way triptans do, it fills a gap for migraine patients who have heart disease, uncontrolled high blood pressure, or a history of stroke, since those conditions often rule out triptan use.
People with severe liver or kidney impairment may need dose adjustments or may not be candidates for the medication. If you’re currently taking a strong CYP3A4 inhibitor and can’t stop it, Ubrelvy is not an option for you.